Skip to main content

Advertisement

Table 1 Patient characteristics

From: Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer

  Patients retaining trastuzumab Patients halting trastuzumab
  Percentage Number 59 Percentage Number 23
Age in years, mean (range)a 51 (26–74) 58 (36–77)
   <50 years 41 24 22 5
   ≥ 50 years 59 35 78 18
Oestrogen receptor/Progesterone receptor
   +/+ 49 29 43 10
   +/- 10 6 9 2
   -/- 39 23 39 9
   Unknown 2 1 9 2
Node     
   Negative 12 7 13 3
   Positive 66 39 52 12
   Unknown 22 13 35 8
Grade     
   1–2 10 6 26 6
   3 54 32 43 10
   Unknown 36 21 31 7
   Adjuvant Therapy     
   Anthracycline 44 26 31 7
   Anthracycline/taxane 10 6 13 3
   No anthracycline/taxane 46 27 56 13
HER2     
   2+b 12 7 9 2
   3+ 56 33 48 11
   Other (positive)c 32 19 43 10
Site of disease before trastuzumab therapyd
   1 site 59 35 78 18
   ≥ 2 sites 41 24 22 5
   Bone   23   5
   Liver   14   7
   Lung   15   7
   Nodes   9   2
   Skin   9   4
   Other   13   3
  1. aAge at the time when trastuzumab therapy was started. bAll 2+ patients had amplification of HER2 gene (fluorescence in situ hybridization-positive). cPositive was indicated by a pathologist as intense and diffuse membrane staining in more than 10% of tumor cells. dSite information refers to the start of trastuzumab treatment.